ACC 2024: SHASTA-2 Final Study Results
Daniel Gaudet, MD, PhD
Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
Christie M. Ballantyne, MD, FACP, FACC
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
Perspectives on the results of recent clinical outcomes trials with EPA prevention
P. Gabriel Steg, MD
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Erik Stroes, MD, PhD
Challenges in ASCVD reduction and TG-related risk
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
Prof. Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Fabrice Martens, MD, PhD, FESC
PCSK9i: Benefits across the spectrum of cardiovascular disease
The evolving need and challenges to reach LDL-c targets in high-risk patients
Oral cholesterol-lowering therapies: The basis of prevention
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Exploring the role of a novel CETP inhibitor in lipid management
New insights on CETP inhibition from genetic research and clinical trials
Unmet needs in lowering LDL-c
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.